Addison's Disease Market Report 2026

The addison's disease market size has grown strongly in recent years. It will grow from $2.24 billion in 2025 to $2.46 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to limited awareness of addison's disease, restricted access to diagnostic facilities, reliance on traditional corticosteroid therapies, growing prevalence of autoimmune disorders, increasing hospital and clinic infrastructure.

The addison's disease market size is expected to see strong growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to development of targeted adrenal insufficiency therapies, rising adoption of patient monitoring technologies, expansion of diagnostic laboratories, increasing research in autoimmune and adrenal disorders, growth in personalized medicine initiatives. Major trends in the forecast period include rising adoption of hormone replacement therapies, increasing use of diagnostic laboratory testing, growth in hydrocortisone and fludrocortisone prescriptions, expansion of autoimmune disease research, focus on early diagnosis and patient monitoring.

The growing prevalence of autoimmune diseases is expected to drive the growth of the Addison's disease market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy tissues, causing inflammation and damage. Factors such as genetic predisposition, environmental influences like pollutants and dietary changes, and lifestyle factors such as stress and physical inactivity contribute to the rising prevalence of autoimmune diseases. This increase also raises the likelihood of co-occurrence with Addison's disease, as many patients develop multiple autoimmune conditions. For instance, in March 2025, according to the Sjögren's Foundation, a US-based non-profit organization, autoimmune illnesses affect over 50 million Americans, representing about 8% of the country’s population. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the Addison's disease market.

Major companies operating in the Addison's disease market are focusing on innovations such as regenerative therapies to expand treatment options, improve patient outcomes, and potentially reduce lifelong reliance on hormone replacement therapy by stimulating natural adrenal function. Regenerative therapies involve medical approaches designed to replace or regenerate human cells, tissues, or organs to restore normal function and promote healing in cases of disease, injury, or degeneration. For instance, in July 2024, Eton Pharmaceuticals, Inc., a US-based public pharmaceutical company specializing in rare disease treatments, announced the FDA's acceptance of its New Drug Application (NDA) for ET-400, a proprietary hydrocortisone oral solution. ET-400 offers easier storage and transport compared to other formulations that may require refrigeration, provides a liquid format suitable for young patients who have difficulty swallowing tablets, and allows for precise dosing.

In March 2025, CROSSJECT, a France-based specialty pharmaceutical company, partnered with Eton Pharmaceuticals, Inc., to develop and commercialize a ready-to-use hydrocortisone formulation (ET-800) for the treatment of adrenal insufficiency crises. Through this collaboration, CROSSJECT aims to leverage Eton’s regulatory and commercial expertise in the U.S. hospital market to bring its innovative hydrocortisone therapy to patients. Eton Pharmaceuticals, Inc. is a US-based rare-disease pharma company focused on addressing adrenal insufficiency, the primary hormonal deficiency in Addison’s disease.

Major companies operating in the addison's disease market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Bayer AG, Sanofi SA, AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Lupin Ltd.

North America was the largest region in the addison's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the addison's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the addison's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the addison's disease market by increasing costs of imported corticosteroids, hydrocortisone, fludrocortisone, and diagnostic equipment. Segments such as oral corticosteroids and laboratory testing are most affected, particularly in asia-pacific and european regions that rely heavily on imports. The tariffs have led to higher treatment costs and supply chain adjustments. However, they also encourage local production of drugs and diagnostics, boosting domestic capabilities and regional self-sufficiency.

The addison's disease market research report is one of a series of new reports that provides addison's disease market statistics, including addison's disease industry global market size, regional shares, competitors with a addison's disease market share, detailed addison's disease market segments, market trends and opportunities, and any further data you may need to thrive in the addison's disease industry. This addison's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Addison's disease is a rare disorder in which the adrenal glands produce inadequate amounts of cortisol and aldosterone due to damage, often caused by an autoimmune response. Symptoms include fatigue, muscle weakness, weight loss, low mood, and changes in the skin. Lifelong hormone replacement therapy is necessary to manage the condition and prevent severe complications, such as adrenal crisis.

The main types of Addison's disease are primary adrenal insufficiency, secondary adrenal insufficiency, and tertiary adrenal insufficiency. Primary adrenal insufficiency occurs when the adrenal glands produce insufficient cortisol and sometimes aldosterone due to damage or dysfunction of the glands. These conditions are managed using various drug classes, including oral corticosteroids, hydrocortisone, fludrocortisone, and corticosteroid injections. Diagnosis generally involves laboratory and imaging tests to assess adrenal gland function. Several end users, such as hospitals, clinics, diagnostic laboratories, and other healthcare providers, are involved in patient care.

The addison's disease market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The addison's disease market also includes sales of adjunct therapies, diagnostic tools, adrenocorticotropic hormone (ACTH) stimulation test kits, blood cortisol, and ACTH testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.